SWITZERLAND: THOMMEN Medical IMPLANT SYSTEM

Red Dot Design Award Winner 2011


Thommen Medical was awarded with the reddot design award 2011 for APLIQUIQ, its unique conditioning system. APLIQUIQ is the fast and effective chairside conditioning system used to produce the superhydrophilic implant surface INICELL.

The reddot award is the most renowned international design prize existing since 1955. A high-level jury assessed the product in detail based on criteria such as design, functionality, degree of innovation, ergonomics and quality. 1700 companies from 60 different countries have submitted 4433 products, from which APLIQUIQ was one of the selected winners.

The reddot award is the international benchmark of excellence and uniqueness.

Demonstrated at Toronto 19th Congress Canadian Academy of Restorative Dentistry and Prosthodontics at Fairmont ROYAL YORK.

40% OSSEOINTEGRATION in three weeks.

Canada: info@thommenmedical.ca

Dental surgeons interested in the THOMMEN IMPLANT SYSTEM include

Robin D. Listrom, DMD, DOMSA, MSc.

Dr. Listrom obtained his dental qualification from the University of Saskatchewan. After three years of general practice, he entered oral surgery training at the University of Toronto, receiving his diploma in oral and maxillofacial surgery and anaesthesia in 1981, a U. of T. Fellowship in 1982, and a Medical Research Council Fellowship from 1982 - 1984. In 1984, Dr. Listrom obtained his Master of Science degree by thesis from the University of Toronto. He holds the rank of Assistant Professor at U. of T., and was actively involved with post graduate teaching at that university for over twenty years.

Dr. Listrom has been involved with implant related research and teaching since the introduction of implants to North America. He is one of the first Canadian fellows of the International Team for Implantology (ITI).

Currently, Dr. Listrom is Head of the Division of Oral and Maxillofacial Surgery at the Credit Valley Hospital.

Affiliations

Ontario Dental Association

Canadian Association of Oral and Maxillofacial Surgeons

Royal College of Dentists of Canada

Royal College of Dental Surgeons of Ontario

Ontario Society of Oral and Maxillofacial Surgeons

NORWAY: ALGETA ALPHARADIN (radium-223 cl.)

Algeta is a focused oncology company developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. These alpha-pharmaceuticals for the treatment of patients with cancer harness the unique characteristics of alpha particle emitters. The lead product is potent against cancer cells, remarkably well tolerated and convenient to use.




Algeta’s initial focus is on treating bone metastases, a serious clinical development of advanced cancer for which few specific treatments exist, and which represents an area of significant commercial potential.



The Company’s lead product, Alpharadin® (radium-223 chloride), is a first-in-class, targeted alpha-pharmaceutical that is in a global phase III clinical trial (ALSYMPCA) to treat bone metastases resulting from castration-resistant prostate cancer (CRPC).



In September 2009, Algeta entered into an $800 million agreement with Bayer Pharma AG for the development and global commercialization of Alpharadin® in prostate and other major cancers that frequently spread to bone.



The Company is headquartered in Oslo, Norway, and was founded in 1997 by Dr. Roy H. Larsen from the University of Oslo and Professor Øyvind S. Bruland, an oncologist at Rikshospitalet-Radiumhospitalet HF, a leading cancer research center.



Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).